Has Kathryn Peterson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $111,319 in general payments to Kathryn Peterson, MD across 83 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kathryn Peterson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kathryn Peterson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kathryn Peterson, MD

Gastroenterology · Salt Lake City, UTNPI 1225128846

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $92,353 of the $111,319 with a category attached, or 83.0%. 19 manufacturers reported payments, led by Sanofi at 31.2% of the total. 2025 is the largest year on record at $26,449, 2.2 times the $12,187 reported in 2019. Among gastroenterology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$111,319in general payments, 2019–2025

Across 83 payments — averaging $1341.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$35K
Regeneron$16K
Takeda Pharmaceuticals U.S.A., Inc.$15K
E.r. Squibb & Sons, L.L.C.$10K
Shire North American Group Inc$6K
Eli Lilly Export S.A. Puerto Rico Branch$5K
plus $25K from 13 others

$1,244,800in research payments, 2019–2025

Across 144 payments — averaging $8644.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$566K
Regeneron$465K
Pfizer$109K
Adare Pharmaceuticals, Inc.$54K
Bristol Myers Squibb$30K
UCB Biosciences Inc.$18K
plus $3K from 3 others

What the payments were for

Consulting fees$92,35383%
Speaking & faculty fees$11,42910%
Travel & lodging$5,1005%
Food & beverage$2,4362%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	16	$34,772
Regeneron	8	$16,279
Takeda Pharmaceuticals U.S.A., Inc.	12	$15,361
E.r. Squibb & Sons, L.L.C.	4	$9,793
Shire North American Group Inc	8	$5,544
Eli Lilly Export S.A. Puerto Rico Branch	1	$4,750
Regeneron Healthcare Solutions, Inc.	9	$4,066
Bristol Myers Squibb	6	$3,909
AstraZeneca	3	$3,880
Astrazeneca UK Limited	1	$3,222
Pfizer	3	$2,046
Blueprint Medicines Corporation	1	$2,022
Sanofi-aventis U.S. LLC	2	$1,603
Eli Lilly	2	$1,439
Lucid Diagnostics Inc.	1	$1,000
Adare Pharmaceuticals, Inc.	3	$801
Amgen	1	$723
Boston Scientific	1	$106
Phathom Pharmaceuticals, Inc.	1	$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$31,384
FASENRA$5,491
EOHILIA$4,250
VELSIPITY$2,046
AYVAKIT$2,022
ESOCHECK CCD CELL COLLECTION DEVICE$1,000
TEZSPIRE$723

How this compares

$111,319 in reported general payments places this provider in the 95th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah →

Medicare billing

Part B allowed, 2024

$25,510

Medicare patients

Services billed

217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
NucalaMepolizumab	12	$132,424
Omeprazole	23	$518

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Salt Lake City

Terry BoxSalt Lake City$302K
Richard GilroySalt Lake City$192K
John FangSalt Lake City$12K
Iqbal SandhuSalt Lake City$10K
John ValentineSalt Lake City$9K
Ann FlynnSalt Lake City$6K
Suryanarayana ChallaSalt Lake City$6K
Jason WillsSalt Lake City$6K
Chaya KrishnamurthySalt Lake City$5K
Ramon Minjares GranilloSalt Lake City$4K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →